Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

H. Hohnloser, Stefan; John Camm, A.; Cappato, Riccardo; Diener, Hans‐Christoph; Heidbüchel, Hein; Mont, Lluı́s; A. Morillo, Carlos; Abozguia, Khalid; Grimaldi, Massimo; Rauer, Heiko; Reimitz, Paul‐Egbert; Smolnik, Rüdiger; Mönninghoff, Christoph; Kautzner, Josef

doi:10.1093/eurheartj/ehz190

Public

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

Published in European Heart Journal • Mar 25, 2019

Authors:

Stefan H. Hohnloser

A. John Camm

Riccardo Cappato

Abstract

AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, paralle...

Subject

Medicine

Edoxaban

Atrial fibrillation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!